Merck Serono has received a ‘complete response letter’ from the US Food and Drug Administration rejecting its proposed multiple sclerosis treatment, cladribine. The company withdrew its European application for the same drug in February. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
